Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates

Group 1 - Novo Nordisk's ADRs rose in intraday trading after an Oxford study linked its Ozempic diabetes drug to lower rates of dementia and various mental problems [1][2] - The study published in The Lancet's eClinicalMedicine journal indicated that patients on Ozempic had a 48% lower risk of dementia after one year compared to those taking sitagliptin [1] - The active ingredient semaglutide in Ozempic and Wegovy is being explored for additional uses beyond diabetes and weight loss, including potential treatment for alcoholism and alcoholic liver disease [2] Group 2 - As of 11 a.m. ET, Novo Nordisk's ADRs increased by 2.6% to $143.39, marking a year-to-date gain of approximately 40% [2] - Eli Lilly's shares, which produce competing medications Mounjaro and Zepbound, have also surged, with a 62% year-to-date increase attributed to rising sales of weight-loss drugs [2]